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 
Abstract— Early diagnosis of Alzheimer’s Disease (AD) is 
widely regarded as necessary to allow treatment to be started 
before irreversible damage to the brain occur and for patients 
to benefit from new therapies as they become available.  Low-
cost point-of-care (PoC) diagnostic tools that can be used to 
routinely diagnose AD in its early stage would facilitate this, 
but such tools require reliable and accurate biomarkers. 
However, traditional biomarkers for AD use invasive 
cerebrospinal fluid (CSF) analysis and/or expensive 
neuroimaging techniques together with neuropsychological 
assessments. Blood-based PoC diagnostics tools may provide a 
more cost and time efficient way to assess AD to complement 
CSF and neuroimaging techniques. However, evidence to date 
suggests that only a panel of biomarkers would provide the 
diagnostic accuracy needed in clinical practice and that the 
number of biomarkers in such panels can be large. In addition, 
the biomarkers in a panel vary from study to study. These 
issues make it difficult to realise a PoC device for diagnosis of 
AD. An objective of this paper is to find an optimum number of 
blood biomarkers (in terms of number of biomarkers and 
sensitivity/specificity) that can be used in a handheld PoC 
device for AD diagnosis. We used the Alzheimer’s disease 
Neuroimaging Initiative (ADNI) database to identify a small 
number of blood biomarkers for AD. We identified a 6- 
biomarker panel (which includes A1Micro, A2Macro, AAT, 
ApoE, complement C3 and PPP), which when used with age as 
covariate, was able to discriminate between AD patients and 
normal subjects with a sensitivity of 85.4% and specificity of 
78.6%. 
 
Index Terms— AD, Machine Learning, Classification, ADNI. 
I. INTRODUCTION 
AD is an age related neurodegenerative disease [1] which 
leads to old age disability, institutionalisation and death 
within 10 years of clinical symptoms [2]. In the UK, it is 
estimated that 2 million people will suffer from dementia by 
2050, with a total annual cost of care of £78 million [3]. 
There is currently no cure for AD but simple and inexpensive 
PoC diagnostic tools that can routinely diagnose AD in its 
early stage are widely regarded as necessary [4]. This would 
allow treatment to be started before irreversible damage to 
the brain occurs and enable patients to get maximum benefit 
from new therapies when they become available.  Although 
traditional biomarkers for AD have reached clinical 
application, they may be difficult to use in handheld PoC 
diagnostic tools because they are based on  invasive 
cerebrospinal fluid (CSF) analysis and/or expensive 
neuroimaging techniques together with neuropsychological 
assessments that take a long time [5]. Blood-based AD 
biomarkers may provide a more cost and time efficient way 
to assess AD to complement traditional biomarkers because 
 
 
obtaining blood samples is far less complex. Several studies 
have identified promising blood biomarkers for AD [6]–[12]. 
A recent review identified 163 candidate blood biomarkers 
for AD from 21 studies. These biomarkers had different 
concentration level in the blood of AD patients compared to 
normal elderly subjects [13]. However, there has been a 
failure to replicate many blood biomarker discovery studies 
due to many factors, including the use of different proteomic 
technologies, the use of different research cohorts,  data over-
fitting, and  differences in sample collection methods [14]. 
Some studies have tried to identify blood biomarkers that are 
specific to a particular aspect of AD, e.g.  cognitive decline 
[15] brain atrophy [12] and neocortical amyloid burden [6].  
Yet despite much progress none of the identified blood 
biomarkers have been used in PoC tools for AD [16].   
Despite the limitations, there is evidence from various 
studies to suggest that a panel of biomarkers would provide 
the diagnostic accuracy needed in clinical practice [17]-[21]. 
Each study identified different panels of different biomarkers 
with differing panel sizes. Furthermore, some of the 
identified panels are quite large making their realisation in 
PoC devices difficult. As yet there has not been any panel 
identified that can be used in a handheld PoC diagnostic tool 
for AD. However, technological advances in machine 
learning and computing power may enable the identification 
of an optimum number of biomarkers (in terms of the number 
of biomarkers and sensitivity/specificity) from proteomic 
datasets. 
An objective of the research project on which this paper is 
based is to develop a novel handheld graphene-based PoC 
diagnostic tool for diagnosis of AD. In this study, the focus is 
to investigate validated blood-based biomarkers with a view 
to finding an optimal panel of blood biomarkers that could be 
used in such a tool. A literature review of blood biomarker 
studies was firstly conducted to identify the most validated 
blood biomarkers for AD. The concentrations of identified 
biomarkers were characterised for AD and controls using 
ADNI proteomic database. Univariate analysis of individual 
biomarkers was carried out to determine candidate 
biomarkers that may be included in biomarker panels. 
Machine learning was then used to different panels from 
candidate biomarkers with good diagnostic value.  
 The panel that had acceptable clinical performance with 
the least number of biomarkers was selected as the optimal 
panel.  The study identified an optimal panel of 6 biomarkers 
panel consisting of α-1 Macroglobulin, α-2-macroglobulin, α-
1 Antitrypsin, Apolipoprotein E, complement C3 and 
Pancreatic Polypeptide. The panel of biomarkers was able to 
discriminate between AD patients and normal elderly 
subjects with sensitivity and specificity values of 85.4% and 
78.6%, respectively.  
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II. METHODS 
The ADNI proteomic database (http://adni.loni.ucla.edu) 
was used in this study. More information about the ADNI 
proteomic dataset can be obtained from http://www.adniinfo. 
org. A literature review was carried out to identify the most 
cross-validated biomarkers for AD. The biomarkers 
identified from the literature review were extracted from the 
ADNI proteomic database for AD and controls subjects. The 
extracted data was then pre-processed to remove records in 
which no plasma concentrations were recorded. Any in which 
the MMSE score of any subject did not correlate with their 
dementia diagnosis status was also removed. The data 
contained concentrations of biomarkers identified from the 
literature for 106 AD patients and 51 controls. The mean age 
of AD patients is 74.88 and 74.56 for the normal elderly 
subjects. The average MMSE scores were 22.75 for AD 
patients and 28.36 for controls..  
The concentration of each biomarker for all AD and 
controls and the age of subjects were extracted from the 
dataset. This was used to train supervised machine learning 
algorithms to learn to discriminate between AD and controls 
based only on age and concentrations of individual biomarker 
in blood of the subjects. The diagnostic value of each 
candidate biomarker to discriminate between AD patients and 
control subjects was measured in terms of the area under the 
receiver operating curve (AUC) [22][23]..  
Candidate biomarkers that obtained an AUC of not less 
than 0.6 were considered as candidate biomarkers for 
inclusion in panels. Several machine learning based feature 
selection algorithms were used to search through the space of 
candidate biomarkers with an AUC of over 0.6. This process 
allowed the identification of feature subsets, or panels of 
biomarkers, that may have good diagnostic performance.   
Each identified panel was used to train different machine 
learning classifiers to learn to discriminate AD from controls. 
We trained Naïve Bayes, Logistic, Multilayer Perceptron, 
Random Forest and Support Vector supervised learning 
algorithms. Naïve Bayes classifier had the best results. Naïve 
Bayes classifiers assume that the presence or absence of a 
feature associated with a class is not related to the absence or 
presence of other features within the class. It is suited for 
complex real world applications and has been effectively 
used in clinical decision support systems to identify 
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All data analysis, feature selection and classification tasks 
were performed using Weka open source machine learning 
toolbox [22]. The performance of each panel to classify AD 
versus control subjects was evaluated using 10-fold cross 
validation training and testing methodology. The dataset is 
randomly divided into 10 sub-datasets. One is considered as 
new and unseen test data and the remaining sub datasets are 
considered as the pool of example data cases used to train a 
supervised machine learning algorithm. This process is 
carried out 10 times each time leaving out a different set that 
is used for testing. The performance is accessed using the 
sensitivity, specificity and AUC for the task of classifying 
AD and control subjects. The acceptable diagnostic accuracy 
that is required in clinical practice is a sensitivity and 
specificity greater than or equal to 80% [25]. However, even 
with moderate sensitivity and specificity, a PoC diagnostic 
tool for dementia may still be useful for routine screening of 
AD. Therefore, a threshold of 75% was set for sensitivity and 
specificity in determining acceptable panel of biomarkers 
performance. The smallest panel that achieved sensitivity and 
specificity values of over 75% was considered the optimal 
biomarker panel for use in the proposed handheld PoC 
diagnostic device for AD.   
III. RESULTS 
A review of the literature identified a total of 163 
candidate blood biomarkers from 22 studies that have been 
validated at least twice. The concentration of these 
biomarkers for AD and control subjects were extracted from 
the ADNI database were analysed. Table 2 shows the 
concentration levels of some of these biomarkers in AD and 
control subjects that were identified from the review and 
which have been validated in at least three different studies. 
The data shows that the biomarkers are differently expressed 
in AD and controls. These biomarkers have been validated at 
least twice by different biomarker discovery studies. Three of 
these biomarkers, A2Macro (α2-Macroglobulin), Fibrinogen 
and CFH (complement factor H) have been shown to be 
associated with brain amyloid burden [6]. C3 (complement 
C3),  fibrinogen and A1Micro (α1 microglobulin) have been 
shown by [26] to be strong predictors of AD pathology.  
A total of 63 biomarkers gave an AUC of greater than 0.6 
when used with age as covariate for the task of classifying 
AD and controls. Table 3 shows the results of the univariate 
analysis biomarkers that have the most diagnostic value in 
discriminating between AD and controls are shown. 
Eotaxin_3 (Eotaxin 3), IgM (Immunoglobulin), ApoE 
(Apolipoprotein E), A1Micro (Alpha-1 Microglobulin), 
PLGF (Placenta Growth Factor), PYY (Peptide YY) , PPP 
(Pancreatic Polypeptide), A2Macro, CRP (C-Reactive 
Protein) and EGF (Epidermal Growth Factor), with age as 
covariate, achieved the highest performance with an AUC of 
greater than 0.648. Table 1 shows the description of some of 
the biomarkers. Table 1 shows the description of some of the 
biomarkers. 
Table 1: Description of some of the biomarkers  
Biomarker Name Biomarker Name 
CLU Clusterin ANG2 Angiopoietin 2 
AAT Alpha-1 Antitrypsin CD40 CD 40 Antigen  
IL_3 Interleukin-3 Cortisol Cortisol 
IGFBP Insulin-like Growth Factor-Binding Protein C Peptide C Peptide 
Table 2: Characterisation of candidate biomarkers 
  
Biomarker Min (max) Avg. (Std.) Min (Max) Avg. (Std.) 
Eotaxin_3 1.544 (3.09) 2.618 (0.21) 1.544 (3.31) 2.383 (0.41) 
IgM 0.509 (0.90) 0.187 (0.24) -0.06 (0.90) 0.377 (0.23) 
ApoE 1.23 (2.23) 1.712 (0.19) 1.505 (2.19) 1.855 (0.14) 
A1Micro 0.875 (1.38) 1.115 (0.10) 0.839 (1.32) 1.036 (0.10) 
PLGF 4.65 (77) 27.99 (15.0) 16 (61) 36.53 (10.4) 
PYY 1.398 (3.076) 2.075 (0.32) 1.398 (2.42) 1.848 (0.30) 
PPP -0.004 (3.15) 2.149 (0.41) 1.23 (2.62) 1.969 (0.32) 
A2Macro -0.119 (0.45) 0.075 (0.09) -0.137 (0.34) 0.025 (0.10) 
CRP -0.824 (1.71) 0.148 (0.63) -0.77 (1.34) 0.315 (0.47) 
EGF 0.176 (2.90) 1.532 (0.59) 0.602 (2.70) 1.688 (0.491 
IGFBP 1.477 (2.19) 1.91 (0.11) 1.491 (2.40) 1.883 (0.19 
IL_3 -2.495 (-1.06) -1.723 (0.28) -2.046 (-1.15) -1.618(0.21) 
B2M 0.114 (0.924) 0.346 (0.17) 0.079 (0.69) 0.29 (0.11) 
Fibrinogen 0.007 (14) 6.769 (2.06) 3 (10) 6.41 (1.31) 
ANG2 0.114 (0.954) 0.614 (0.12) 0.322 (1.07) 0.599 (0.14) 
CD40 -0.367 (0.255) -0.094 (0.12) 0.337 (0.14) -0.111 (0.11) 
Cortisol 1.982 (2.635) 2.207 (0.11) 1.869 (2.58) 2.174 (0.14) 
C Peptide -0.167 (0.74) 0.36 (0.18) -0.046 (0.99) 0.374 (0.21) 
C3 0.709 (0.46) 0.285 (0.08) 0.079 (0.46) 0.259 (0.07) 
CFH 829 (7990) 4055 (1325) 1080 (6520) 3718 (1175) 
CLU 2.35 (2.81) 2.516 (0.09) 2.356 (2.643) 2.502 (0.079 
EGRF 2.5 (6.5) 4.515 (0.76) 2.5 (6) 4.517 (0.656) 
AAT 0.079 (0.65) 0.47 (0.096) 0.204 (0.69) 0.443 (0.85) 
Age 55 (89) 74.87 (8.052) 62 (90) 75.15 (5.78) 
Education 4 (20) 15.116 (3.207) 8 (20) 15.67 (2.78) 
 
Table 3:  Identified panels of biomarkers 
 
Biomarker AUC Biomarker AUC 
Eotaxin_3 0.731 B2M 0.644 
IgM 0.727 Fibrinogen 0.639 
ApoE 0.723 ANG2 0.638 
A1Micro 0.717 CD40 0.638 
PLGF 0.706 Cortisol 0.638 
PYY 0.698 C Peptide 0.624 
PPP 0.68 C3 0.621 
A2Macro 0.678 CFH 0.605 
CRP 0.675 CLU 0.602 
EGF 0.661 EGRF 0.602 
IGFBP 0.648 AAT 0.602 
IL_3 0.648     
 
Table 4 shows four panels that were identified and their 
performance investigated. The panels have different sizes 
ranging from 4 to 16 and used different combinations of 
candidate biomarkers. ApoE was used in all panels and C3, 
CRP, IGM and PYY were used in three out of the four 
panels. A2Macro, AAT, CD40, CLU, Cortisol and IL_3 were 
used in two panels. 
Table 4: Identified biomarker panels 
Panel 1 Panel 2 Panel 3 Panel 4 
ApoE ApoE ApoE A1Micro 
A2Macro CRP C3 A2Macro 
AAT IGM CD40 AAT 
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Each panel of biomarkers was used to train a machine 
learning classifier. The performance of the biomarkers was 
evaluated in terms of the sensitivity, specificity, AUC and 
accuracy in classifying AD and controls. The results of 
evaluating the performance of the panels are presented in 
Table 5. The minimum sensitivity for all the panels was 0.68 
and maximum was 0.854 and the minimum and maximum of 
the specificity was 0.75 and 0.796, respectively. The average 
sensitivity and specificity value was 0.77. Only two of the 
panels achieved a sensitivity and specificity of more than 
75%. Panel 4 obtained the optimal performance of sensitivity 
value of 0.85, specificity of 0.78, an AUC value of 0.85 and 
an accuracy of classifying AD and controls of 83.6%. 
Table 5: Biomarker panel performance 
Panel 1 2 3 4 
Size 16 4 9 6 
Sensitivity 0.7 0.68 0.78 0.85 
Specificity 0.7 0.75 0.79 0.78 
AUC 0.8 0.82 0.83 0.85 
Accuracy 76.3 70.3 78.9 83.6 
 
The receiver operating curve for Panel 4 is shown in 
Figure 1. This panel has the smallest number of biomarkers 
and meets the specified performance threshold for use in the 
proposed handheld PoC tool for routine clinical use. 
 
Figure 1: The receiver operating curve for 6-panel biomarker 
panel 
IV. CONCLUSIONS AND DISCUSSIONS 
This study investigated the determination of an optimum 
number of blood biomarkers that can be used in a diagnostic 
PoC tool for routine diagnosis of dementia from blood 
  
samples in minutes. ADNI proteomic database was used to 
characterise the concentration of the identified biomarkers in 
AD and control patients. A univariate data analysis was 
performed to determine which of the identified biomarkers 
have significant diagnostic value for them to be potentially 
used in diagnoses of AD. These were then used in a 
multivariate data analysis to identify a combination of 
biomarkers which can be used as a panel of biomarkers that 
could be used to diagnose AD with clinically acceptable 
performance. 
A panel of 6 biomarkers which consists of A1Micro, 
A2Macro, AAT, ApoE, C3 and PPP, together with subjects’ 
age as covariate, was able to classify AD and control 
subjects with a sensitivity of 85.4% and specificity of 
78.6%. This panel has a high enough performance to be used 
in a handheld PoC tool for dementia diagnosis. Results of 
this study are promising and suggest that, a panel of only 6 
blood biomarkers may be used in a PoC tool for the 
diagnosis of AD based on blood samples. As future work, 
the results will be validated using a different proteomic 
dataset. 
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